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immunogenicity met all licensure criteria, clinical efﬁcacy
was demonstrated and safety proﬁle was comparable to egg
derived vaccines1.14th International Congress on Infectious Diseases (ICID) Abs
with permanent sequelae such as cognitive or neuropsy-
chiatric complaints, dysphasia, hearing defects and spinal
paralysis. The severity of the disease and the lack of causal
therapy emphasize the need for prevention of tick borne
encephalitis (TBE) by vaccination. Inactivated, whole virus
TBE vaccines (FSME IMMUN, Baxter and Encepur, Novartis)
are widely used in Europe. In recent years a full clini-
cal development program, including safety, immunogenicity
and seropersistence studies has been conducted for FSME-
IMMUN in all age groups. Antigen doses of 2.4g and 1.2g
were identiﬁed as optimal for adults and children, respec-
tively. In an ongoing study, the safety and immunogenicity of
FSME-IMMUN 0.25ml Junior and Encepur 0.25ml Children are
being investigated in children 1 to 11 years of age. A total of
150 and 152 subjects were enrolled in the FSMEIMMUN and
Encepur group, respectively. Immunogenicity was assessed
by two different ELISA assays using antigens homologous to
the TBEV strains of either FSME IMMUN (IMMUNOZYM1), or
Encepur (Enzygnost2). Four weeks after the second vacci-
nation, in the FSME-IMMUN group, 100% of subjects were
seropositive in both the IMMUNOZYM- (>126 VIEU/ml) and
the Enzygnost ELISA (>10.32U/ml) compared with 94.0%
and 96.7% respectively, in the Encepur group. Geometric
mean concentrations (GMC) measured by IMMUNOZYM ELISA
were 3026 in the FSME-IMMUN and 678 in the Encepurgroup.
GMCs measured with the Enzygnost ELISA were 163.3 (FSME-
IMMUN) and 93.7 (Encepur). Local reactions after the 1st
vaccination occurred in 12.7% with FSME-IMMUN and in 28.9%
with Encepur. The rate of systemic reactions was compara-
ble: 9.3% (FSME-IMMUN) and 11.8% (Encepur). The presently
marketed TBE vaccines represent highly effective tools for
the prevention of this continuously spreading disease.
doi:10.1016/j.ijid.2010.02.1862
37.003
Strategies for the Development of New Vaccines
S.A. Plotkin
University of Pennsylvania and Vaxconsult, Doylestown, PA,
USA
The reputation of vaccination rests on a two hundred
year old history of success against major infectious dis-
eases. In general, two achievements have been crucial to the
success of vaccines: the induction of long-lasting immuno-
logical memory in individuals and the stimulation of a herd
immunity that enhances control of infectious diseases in
populations. However, when one reviews the vaccines now
available it is apparent that most successes have been
obtained when the microbe has a bacteremic or viremic
phase during which it is susceptible to the action of neu-
tralizing antibodies, and before replication in the particular
organ to which it is tropic.Success has also been achieved against some agents repli-
cating on respiratory or gastrointestinal mucosae, against
which it has been possible to induce immune responses act-
ing locally as well as systemically.
1 IMMUNOZYM FSME IgG, Progen.
2 Enzygnost TBE, Dade Behring.
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Control of intracellular pathogens has not been achieved,
xcept partly with the BCG vaccine against tuberculosis,
nd modern efforts are directed towards pathogens against
hich cellular immune responses are critical.
Newer approaches in vaccine production such as nucleic
cid immunization, vectors, reverse genetics and additional
outes of administration may circumvent prior difﬁculties.
he target of vaccination will shift towards adolescents,
dults, patients in hospital and those with chronic diseases
nd possibly will extend to therapy as well as prevention.
he major scientiﬁc problems to be solved are maintenance
f immune memory, immaturity and post-maturity of the
mmune system, and adjuvants capable of stimulating selec-
ive cell types.
oi:10.1016/j.ijid.2010.02.1863
7.004
ew Technology Update: Cell Culture derived seasonal
nd pandemic ﬂu vaccine
artmut J. Ehrlich ∗, P. Noel Barrett
Baxter Innovations GmbH, Vienna, Austria
The Vero cell line is the most widely accepted contin-
ous cell line by regulatory authorities and has been used
ince decades for the production of, e.g. polio-, rabies- and
otavirus vaccines. Here we report on the clinical charac-
erization of Vero cell derived inactivated pandemic- and
easonal inﬂuenza vaccines.
A whole virus H5N1vaccine based on (Viet-
am/1203/2004/H5N1, clade 1) was demonstrated to
e safe and had an excellent tolerability proﬁle. A dose
f 7.5 $g of a non-adjuvanted vaccine formulation was
ighly immunogenic and induced antibodies neutralizing
omologous strains as well as viruses from other H5N1
lades. A booster dose of a heterologous (clade 2) H5N1
accine 12-17 months later resulted in enhanced antibody
esponses against both the original (clade 1) and the booster
clade 2) strain, indicative of .cross-protective memory.
A vaccine against the current pandemic H1N1 strain is
eing studied in adults and children. In adults, two doses of
.5$g antigen induced seroprotective HA antibody titers in
9% - 91% of subjects. An ongoing pediatric study demon-
trated that after the second dose 100% seroprotection (HI
ssay) was attained in the 3-8 and 9-17 year old cohorts.
Vero cell derived trivalent seasonal inﬂuenza vaccines
split virion), using wildtype virus seed stocks were devel-
ped and extensively tested in human studies. Their1 This Project has been funded in whole with Federal (United
tates Government) funds from the Ofﬁce of the Assistant Secre-
ary for Preparedness and Response, Ofﬁce of Biomdical Advanced
esearch and Development Authority, under contract NUMBER
HS0100200600013C to DynPort Vaccine Company LLC, a CSC
ompany, under No.:S1008307 awarded to Baxter Healthcare Cor-
oration.
e th In
p
a
d
T
t
3
F
I
r
l
r
d
i
p
e
r
t
d
a
p
t
r
p
i
d
h
T
i
m
i
r
e
e
l
w
t
a
c
c
s
d
m
d
3
C
A
C
a
l
r
a
i
t
d
p
m
t
t
a
S
l
t
E
d
v
c
t
b
d
s
r
t
a
d
3
N
R
s
t
h
e
t
d
o
a
t
b
r
i
i
(
c
D
b
w
(Spirometra) are much less common. Advances in diagno-
sis, treatment and prevention of these neglected diseases
will be reviewed with emphasis in neurocysticercosis.172 14
These data indicate that ﬂexible and versatile Vero cell
latform can successfully be in the production of pandemic
nd seasonal inﬂuenza vaccines.
oi:10.1016/j.ijid.2010.02.1864
he ill returnee from Latin America (Invited Presen-
ation)
8.001
ebrile Illnesses
. Tellez
Emory University, Atlanta, GA, USA
Roughly 10% of travelers to developing countries expe-
ience a febrile illness during travel or on return. The
ikelihood of developing a medical condition during travel
elates to an individual’s past medical history, travel
estination, duration of travel, level of accommodation,
mmunization history, adherence to indicated chemopro-
hylactic regimens, activities during travel, and history of
xposure to infectious agents prior to and during travel. The
isk for acquiring a tropical infection is primarily affected by
he activities of the traveler. For example, immigrants from
eveloping countries return home to visit friends and rel-
tives (VFR) in their place of birth and usually don’t take
reventive therapy for malaria. Long-term expatriates, on
he other hand, have unique risk proﬁles. Fever is a leading
eason for post travel consultation. Careful questioning of
atients about the pattern of fever and associated symptoms
s useful. Several papers around the world have reported
ata about returning travelers with fever. The Geosentinel
as reviewed its data on 24,920 travelers from 1997 to 2006.
hey reported that 28% of returned travelers seen at clin-
cs presented with fever as their chief reason for seeking
edical care. Fever was a marker of a serious illness requir-
ng hospitalization. In this report, causes of fever varied by
egion visited and by time of presentation after travel. The
xposure history is crucial to the formulation of a differ-
ntial diagnosis. Knowledge of infectious disease outbreaks
ike the novel H1N1 Inﬂuenza pandemics in a speciﬁc region
here the patient has traveled is very helpful. Travelers
o Latin America can be exposed to different infectious
gents that can give a systemic febrile illness. The most
ommon ones include respiratory tract infections, mononu-
leosis, dengue, malaria, and typhoid fever. Sometimes no
peciﬁc cause is reported. Laboratory diagnosis has to be
one promptly and efﬁcaciously to avoid delays in treat-
ent.
oi:10.1016/j.ijid.2010.02.1865
8.002
utaneous Diseases in Returnee Travellers from Latin
merica
. PerretPontiﬁcia Universidad Catolica de Chile, Santiago, Chile
Cutaneous diseases are very frequent in travelers. They
re ranked in the three most common causes of health prob-
dternational Congress on Infectious Diseases (ICID) Abstracts
ems in returned travelers. Some destinations have a higher
isk of cutaneous diseases in travelers, such as the Caribbean
nd Latin America. The origin of most of these dermatolog-
cal disorders is due to infection, but some of them are due
o solar allergies and envenomization. The main cutaneous
iseases observed in travelers are cutaneous larva migrans,
hytophotodermatitis, complicated mosquito bites, pyoder-
as, miyasis and tungiasis.
Risk factors like country of acquisition, age, reason for
ravel, duration of the travel, gender vary according to
he disease. Countries within Latin America with higher risk
re Jamaica, Dominican Republic, Brazil, Belize and Bolivia.
ome risk groups that have been determined for dermato-
ogical conditions include short term travelers, those with
ourism as the purpose of travel, male and young travelers.
valuation of an ill traveler with skin lesions includes very
etailed questions to evaluate the history of exposure, pre-
ention measures, immunization, previous treatment and a
omplete physical examination. Very rarely further diagnos-
ic studies are needed such as blood tests, serology, skin
iopsies, cultures and imaging techniques. Many cutaneous
iseases related to travel can be prevented wearing closed
hoes, avoiding skin contact with some fruit juices and using
epellents to avoid insect bites. Use of anti rabies and anti
etanus vaccines is also recommended for some destinies
nd adventure travels.
oi:10.1016/j.ijid.2010.02.1866
8.003
on-Enteric Helminths Including Cysticercosis
. Isturiz
Centro Medico de Caracas, Caracas, Venezuela
Segmented tapeworms of clinical importance range in
ize from a few centimeters (H. nana and H. diminuta)
o several meters (T. solium and T. saginata) and utilize
umans as deﬁnitive hosts, intermediate hosts or both. Gen-
rally, adult organisms reside and may produce disease in
he gastrointestinal tract and larvae can inhabit and produce
isease in any human tissue. Teniasis results from ingestion
f viable metacestodes of either T. solium or T. saginata)
nd is often asymptomatic, but occasionally serious, life
hreatening illness can result. Cysticercosis is the infection
y Cysticercus cellulosae, the larval stage of T. solium. Neu-
ocysticercosis is the invasion to CNS structures that results
n a variety of neurological illness. Echinococcosis is the
nfection by larvae of E. granulosus Cystic), E. multilocularis
Alveolar) and related species (E. vogeli, E. oligarthus, poly-
ystic). Major epidemiologic and clinical differences exist.
iphyllobotriasis (D. latum) is frequent and is transmitted
y uncooked freshwater ﬁsh. Hymenolepiasis is common in
arm climates. Dipylidiasis (D. caninum) and sparganosisoi:10.1016/j.ijid.2010.02.1867
